The innovations introduced by NEW DEAL strengthen the leadership of Europe in the field of advanced therapies and in particular, in nanotherapies.
An alternative therapy for inflamatory bowel diseases (IBDs)
The goal of the new European project NEW DEAL is to design and validate a new targeted therapy against inflammatory bowel diseases (IBDs). This therapy is aimed at treating patients with Crohn’s disease (CD) and ulcerative colitis (UC), which are chronic and immune-mediated disorders of the gastrointestinal tract. IBDs affect more or less 3 million people in Europe, mainly adolescents and young adults. The patients suffer from diarrhoea, fatigue and abdominal pain; and in the worst cases: bowel perforation, severe bleeding, colorectal dysplasia and cancer.
This treatment might be an alternative to the existing therapies for IBDs. The conventional IBD therapies can only treat half of the patients with UC but not patients with CD; while the biological therapy can only treat a minority of patients with IBDs because of an immunogenicity and an increasing risk of infection.
A nanotherapy targeting the Janus kinases (JAK) 1/3 enzyme
The use of nanotherapy using siRNA targeting specific molecular targets JAK1 / JAK3, recently identified as clinically relevant, is a new approach to treat IBDs, which will consist in an oral administration medicine delivering a targeted and local therapy directly to the inflamed gut, through the gastrointestinal tract.
“The NEW DEAL concept could revolutionize IBD therapies for the great benefit of patients and European healthcare systems, as well as promote the competitiveness of European Biotech/Medtech companies in the near future in the fields of RNAi medicines and targeted therapy through innovative delivery technologies.”
Fabrice NAVARRO, CEA, coordinator of the New Deal project.
Specific objectives of NEW DEAL
- Design and validate a radically improved IBD therapy that specifically targets JAK1 / JAK3 inhibition by means of siRNA and RNAi interference
- Develop advanced technologies for delivering siJAK1 / siJAK3 locally to the inflamed gut
- Promote the clinical translation and the future industrial transfer of this new clinical product for IBD therapy
The NEW DEAL partners
The NEW DEAL project was granted within the Horizon 2020 Program of the European Union after a competitive two-stage selection process. The project started with a kick-off meeting in Grenoble (France) on 27th January 2017 and will be funded for four years.
 Burisch J. et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013 May; 7(4):322-337.